Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Zamarin · SciRah

Researcher profile · Semantic Scholar

D. Zamarin

Share profile

D. Zamarin — researcher profile on SciRah

h-index: 46
Works: 248
Citations: 12K

Most-cited papers

Ovarian cancer-derived IL-4 promotes immunotherapy resistance
G. Mollaoglu, Alexander Tepper, C. Falcomatà, Hunter T. Potak +15 more
2024Cell115 citations Open access
Semantic Scholar
Transgelin 2 guards T cell lipid metabolism and anti-tumor function
S. Hwang, Deepika Awasthi, Jieun Jeong, T. Sandoval +21 more
2024Nature79 citations Open access
Semantic Scholar
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer
Stella V. Paffenholz, Camilla Salvagno, Yu-Jui Ho, Matthew Limjoco +10 more
2022Proceedings of the National Academy of Sciences of the United States of America72 citations Open access
Semantic Scholar
Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling
Yiming Fang, Xue Xiao, Ji Wang, S. Dasari +4 more
2023bioRxiv46 citations Open access
Semantic Scholar
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer
Andrew Mcpherson, I. Vázquez-García, Matthew A. Myers, Duaa H. Al-Rawi +54 more
2025Nature42 citations Open access
Semantic Scholar
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
D. Davar, B. Carneiro, G. Dy, Siddharth Sheth +15 more
2024Journal for ImmunoTherapy of Cancer29 citations Open access
Semantic Scholar
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
Maria M. Rubinstein, Eric Rios Doria, J. Konner, S. Lichtman +19 more
2022Gynecologic Oncology22 citations Open access
Semantic Scholar
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission
B. Manning-Geist, S. Gnjatic, C. Aghajanian, J. Konner +13 more
2023Cancers19 citations Open access
Semantic Scholar
Pathogenic germline variants in non-BRCA homologous recombination genes in ovarian cancer: analysis of tumor phenotype and survival
R. Kahn, P. Selenica, Thomas Boerner, K. Roche +24 more
2023Gynecologic Oncology17 citations Open access
Semantic Scholar
Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype
K. Dessources, Lorenzo Ferrando, Qin Zhou, A. Iasonos +5 more
2023Gynecologic Oncology15 citations Open access
Semantic Scholar
Multiplexed molecular imaging with surface enhanced resonance Raman scattering nanoprobes reveals immunotherapy response in mice via multichannel image segmentation
C. Andreou, Konstantinos Plakas, Naxhije Berisha, M. Gigoux +8 more
2022Nanoscale Horizons15 citations Open access
Semantic Scholar
Abstract CT004: Intratumoral (IT) MEDI1191 + durvalumab (D): Update on the first-in-human study in advanced solid tumors
E. Castañón, D. Zamarin, B. Carneiro, T. Marron +13 more
2023Cancer Research12 citations
Semantic Scholar
Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer
Andrew Mcpherson, I. Vázquez-García, Matthew A. Myers, M. Zatzman +53 more
2024bioRxiv11 citations
Semantic Scholar
Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
L. Moukarzel, Lorenzo Ferrando, H. Dopeso, A. Stylianou +15 more
2022Gynecologic Oncology11 citations Open access
Semantic Scholar
A Convergent uPAR-Positive Tumor Ecosystem Creates Broad Vulnerability to CAR T Cell Therapy
Ze-Da Zhang, Yu-Jui Ho, Xin Fang, Minseo Kim +64 more
2026Cell10 citations Open access
Semantic Scholar
Prognosis of isolated tumor cells and the utility of molecular classification in early-stage endometrioid endometrial cancer
E. Rios-Doria, N. Abu-Rustum, K. Alektiar, V. Makker +9 more
2024International Journal of Gynecological Cancer10 citations Open access
Semantic Scholar
Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix
Sarah H. Kim, Thais Basili, H. Dopeso, Arnaud Da Cruz Paula +24 more
2022Journal of Pathology9 citations Open access
Semantic Scholar
Evolution of peripheral and tumor immune parameters as biomarkers of differential sequencing of immune checkpoint blockade and chemoradiotherapy in locally advanced cervical cancer: An NRG Oncology/GOG Study (006)
D. Zamarin, W. Deng, H. Lankes, S. Ghamande +11 more
2023Gynecologic Oncology7 citations Open access
Semantic Scholar
Safety and immunogenicity of Anti PD-L1 (Atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: an NRG Oncology trial (024)
J. Mayadev, D. Zamarin, W. Deng, H. Lankes +10 more
2022Gynecologic Oncology7 citations
Semantic Scholar
708 MEDI1191 (IL-12 mRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (C/SC) lesions
Michael Abadier, E. Jennings, J. Eyles, P. Martin +17 more
2022Regular and Young Investigator Award Abstracts7 citations Open access
Semantic Scholar
Abstract CT183: First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors
B. Carneiro, D. Zamarin, T. Marron, I. Mehmi +16 more
2022Cancer Research7 citations
Semantic Scholar
Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA
Marc J. Williams, I. Vázquez-García, Grittney K. Tam, Michelle Wu +23 more
2024bioRxiv6 citations Open access
Semantic Scholar
APR-246 increases tumor antigenicity independent of p53
Judith Michels, D. Venkatesh, Cai-Lian Liu, S. Budhu +12 more
2023Life Science Alliance6 citations Open access
Semantic Scholar
Transforming Ovarian Cancer Care by Targeting Minimal Residual Disease
A. Jazaeri, R. Grisham, A. Knisely, Stefani Spranger +22 more
2023i Medicina6 citations Open access
Semantic Scholar
Abstract CT183: Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
B. Izar, D. Zamarin, D. Spigel, C. Hoimes +17 more
2024Cancer Research5 citations
Semantic Scholar
A Phase 2 Study of Dasatinib in Recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, Peritoneum or Endometrium: NRG Oncology/Gynecologic Oncology Group Study 0283
R. O'Cearbhaill, Austin Miller, R. Soslow, H. Lankes +11 more
2023Gynecologic Oncology5 citations Open access
Semantic Scholar
Induction of a CD8 T cell intrinsic DNA damage and repair response is associated with clinical response to PD-1 blockade in uterine cancer
Y. Muroyama, Sasikanth Manne, N. Wellhausen, D. Oldridge +11 more
2022bioRxiv5 citations Open access
Semantic Scholar
Molecular classification of endometrial carcinomas: a singleinstitution review (084)
E. Rios-Doria, N. Abu-Rustum, Mario Leitão, K. Alektiar +8 more
2022Gynecologic Oncology5 citations
Semantic Scholar
A working group report from the 2024 NCI/GCSC endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era.
C. Cosgrove, D. Zamarin, José R. Conejo-Garcia, Kari E. Hacker +7 more
2025Journal of the National Cancer Institute4 citations
Semantic Scholar
Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva
Sara Moufarrij, O. Filippova, Arnaud Da Cruz Paula, Juan Blanco Heredia +8 more
2024International Journal of Gynecological Cancer4 citations
Semantic Scholar
2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both
E. Rios-Doria, N. Abu-Rustum, G. Glaser, M. Mcgree +8 more
2024International Journal of Gynecological Cancer3 citations Open access
Semantic Scholar
Procedural Interventions for Oligoprogression During Treatment with Immune Checkpoint Blockade in Gynecologic Malignancies: A Case Series
Tiffany Y. Sia, V. Wan, Michael Finlan, Qin Zhou +15 more
2024International Journal of Gynecological Cancer3 citations Open access
Semantic Scholar
Transgelin 2 guards T cell lipid metabolic programming and anti-tumor function
S. Hwang, Deepika Awasthi, Jieun Jeong, T. Sandoval +18 more
2023Research Square3 citations Open access
Semantic Scholar
Abstract CT160: Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cance
E. Swisher, L. Duska, E. Hamilton, A. Oza +8 more
2023Cancer Research3 citations
Semantic Scholar
PO005LBA/#1579 A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)
R. O'Cearbhaill, M. Sill, H. Duong, S. Waggoner +16 more
2023Plenary 01: Oral Abstract Presentations3 citations Open access
Semantic Scholar
Cell-free DNA analysis as a molecular tool to monitor response to immune checkpoint inhibition in endometrial cancer.
B. Manning-Geist, J. Patel, A. Marra, Arnaud Da Cruz Paula +8 more
2022Journal of Clinical Oncology3 citations
Semantic Scholar
An integrated approach for the accurate detection of HERV-K HML-2 transcription and protein synthesis
C. Gleason, Sandra Terry, M. Hernandez, Samson T. Jacob +10 more
2025Nucleic Acids Research2 citations
Semantic Scholar
Computational Inference of Metabolic Programs: A Case Study Analyzing the Effect of BRCA1 Loss
M. Masid, Ioanna A. Rota, David Barras, F. de Carlo +9 more
2025bioRxiv2 citations Open access
Semantic Scholar
LB005/#1605 Randomized, phase II/III study of pegylated liposomal doxorubicin, bevacizumab, and atezolizumab in platinum-resistant ovarian cancer (NRG-GY009): clinical outcomes by PD-L1 and T cell infiltration status
R. O'Cearbhaill, D. Zamarin, Michael Sill, H. Duong +16 more
2024Late-Breaking Abstracts2 citations Open access
Semantic Scholar
Abstract 2553: Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes
I. Vázquez-García, F. Uhlitz, N. Ceglia, J. Lim +45 more
2022Cancer Research2 citations
Semantic Scholar
Cancer trials as opportunities to serve and learn from individuals with human immunodeficiency virus
C. Henson, D. Morton, J. Mayadev, S. Wong +1 more
2022Cancer2 citations Open access
Semantic Scholar
A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056).
C. Kyi, Maria M. Rubinstein, P. Shah, Qin C. Zhou +16 more
2022Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract CT244: A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)
D. Spigel, A. Spira, D. Zamarin, D. McDermott +10 more
2022Cancer Research2 citations
Semantic Scholar
Immunogenomic determinants of response to immune checkpoint inhibition in ovarian cancer: Insights from the NRG-GY003 clinical trial
Kelsey R. Monson, Nezar Mehanna, M. Sill, Zhihong Chen +14 more
2026Gynecologic Oncology1 citations
Semantic Scholar
Abstract B056: Thrombospondin-1:CD47 signaling contributes to the development of T cell exhaustion in cancer
Chien-Huan Weng, Anais Assouvie, Lauren Dong, Jean-Christophe Beltra +20 more
2025Cancer immunology research1 citations
Semantic Scholar
A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer.
Melanie W Kier, Erin L. Moshier, S. Blank, M. Hayes +10 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Early-stage uterine papillary serous carcinoma: Clinical outcomes in patients treated with adjuvant chemotherapy and vaginal brachytherapy.
D. Cherry, V. Gupta, J. Bloom, K. Hsieh +5 more
2025Gynecologic Oncology1 citations
Semantic Scholar
Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.
Melissa L. Johnson, John T Hamm, F. Thistlethwaite, Myung-Ju Ahn +12 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract 115: Developing uPAR CAR T Cells for High-Grade Serous Ovarian Cancer
Ze-Da Zhang, Xin Fang, Yu-Jui Ho, Sascha Haubner +21 more
2024Cancer Research1 citations
Semantic Scholar
Abstract 5742: Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
James D. Thomas, Sydney X. Lu, Emma De Neef, Erich Sabio +31 more
2023Cancer Research1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Weigelt×15
Invite
B. Weigelt — researcher profile on SciRah
R. O'Cearbhaill×13
Invite
R. O'Cearbhaill — researcher profile on SciRah
N. Abu-Rustum×12
Invite
N. Abu-Rustum — researcher profile on SciRah
C. Friedman×10
Invite
C. Friedman — researcher profile on SciRah

×10

Invite

C. Aghajanian — researcher profile on SciRah

Sohrab P. Shah×7

Invite

Sohrab P. Shah — researcher profile on SciRah

Invite

Michelle Wu — researcher profile on SciRah

Invite

L. Ellenson — researcher profile on SciRah

C. Aghajanian×6

Invite

C. Aghajanian — researcher profile on SciRah

I. Vázquez-García×5

Invite

I. Vázquez-García — researcher profile on SciRah

Invite

K. Roche — researcher profile on SciRah

Invite

Y. Sonoda — researcher profile on SciRah